Increased P450 aromatase levels in post-menopausal women after acute ischemic stroke

Bharti Manwani (Bharti.Manwani@uth.tmc.edu)
UNIVERSITY OF TEXAS HOUSTON  https://orcid.org/0000-0002-2852-6093

Pamela Fall
UConn Health

Liang Zhu
University of Texas Health Science Center at Houston

Meaghan Roy O’Reilly
University of Texas Health Science Center at Houston

Sarah Conway
Brigham and Women's Hospital

Ilene Staff
Hartford Hospital

Louise D. McCullough
University of Texas Health Science Center at Houston

Research

Keywords: Aromatase, estradiol, testosterone, stroke, sex differences

DOI: https://doi.org/10.21203/rs.3.rs-45331/v3

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Sex differences in stroke have been attributed to the neuroprotective effects of estrogen, yet most clinical trials of estrogen supplementation for stroke prevention have failed. The contribution of sex hormones to stroke outcome remains a subject of debate. Aromatization of testosterone to estradiol in neural tissue leads to sexual differentiation. Emerging data suggests aromatase activity increases in response to brain injury, and increased aromatase expression is seen in the ischemic penumbra in animal models. The objective of this study was to examine the levels of endogenous sex steroids after acute ischemic stroke and determine if levels of sex steroids were associated with acute stroke outcomes.

**Methods:** Peripheral blood from ischemic stroke patients and controls was collected under an approved IRB within 24 hours of symptom onset. 17-β estradiol, testosterone and aromatase levels were measured in the serum of both men and women using ELISA. Hormone levels were compared in men vs. women in stroke and control groups and correlated with outcomes (NIHSS and change in the modified Rankin Scale (mRS), defined as difference of premorbid and discharge mRS) using multivariate regression.

**Results:** We found no significant difference in estradiol levels 24 hours after stroke in men (p=0.86) or women (p=0.10). In men, testosterone significantly decreased after stroke as compared with controls (1.83±0.12 vs 2.86±0.65, p=0.01). Aromatase levels were significantly increased in women after stroke as compared with controls (2.27±0.22 vs 0.97±0.22, p=0.002), but not in men (p=0.84). Estradiol levels positively correlated with change in mRS in both women (r=0.38, p=0.02) and men (r=0.3, p=0.04).

**Conclusions:** Estradiol levels correlated with functional outcomes (change in mRS) in both men and women, at least in the acute phase (24 hours) of stroke. However, no significant difference in estradiol levels is seen 24 hours post stroke in men or women. Testosterone levels decrease at 24 hours after stroke in men. As seen in animal models, aromatase levels increase after acute ischemic stroke, but this was only true for women. These indicate an active aromatization process in post-menopausal women after acute ischemic stroke.

Introduction

It is well established that sex differences exist in stroke incidence, prevelance and outcome in ischemic stroke (1). Elderly women bear the major brunt of stroke disability as compared to men (2, 3). Most of this sexual dichotomy in stroke has been attributed to the effects of sex hormones (4) as preclinical data has consistently shown that estrogens are neuroprotective (5). However, clinical trials of estrogen supplementation have failed. In fact, the Women's Health Initiative (WHI) and Women's Estrogen for Stroke Trial (WEST) trials showed increased mortality in elderly women supplemented with estrogen (6, 7), although there were several issues with the trial design including enrollment of older women many years past menopause (8).

P450 aromatase is the enzyme that actively converts testosterone to estradiol in the embryonic brain. During prenatal development, aromatization of testosterone to estradiol in neural tissue leads to sexual
differentiation/ defeminization of male brain (9, 10). On the other hand, the female brain develops in the absence of estradiol as it is bound to α-fetoprotein, a plasma protein in the periphery (10). Interestingly, increased aromatase expression is seen in ischemic penumbra in animals (11). Administration of aromatase inhibitors or deletion of aromatase increased ischemic damage in experimental stroke models beyond what was seen in ovariectomized mice, suggesting that endogenous extragonadal estradiol production is important in females for neuroprotection (12). However, there are limited studies examining sex steroid levels in humans after ischemic stroke. The aim of this study was to assess the post stroke sex steroid milieu in men and women. Previous studies have focused on either estradiol or testosterone levels in either men or women after stroke. Since there may be a complex dynamics of estradiol, aromatase and testosterone level after stroke, we assessed the levels of these hormones simultaneously in both men and women.

Methods

This study was conducted at Hartford Hospital, CT, a regional tertiary care facility with a Joint Commission certification as a comprehensive stroke center. Serum from patients presenting with focal neurological deficits who consent under an IRB-approved protocol to participate in a biobank study was collected within 24 hours from symptom onset. Serum samples from 102 patients (61 men and 41 women, with 43 men and 32 women in the stroke group and 18 men and 9 women in the control group) were used for this study. Blood samples from patients were collected in vacutainer tubes, allowed to clot for thirty minutes and then centrifuged to obtain serum, as described previously (13). Serum was stored at -80 °C until analysis and each sample was run in duplicates. A blinded investigator performed serum Enzyme-linked immunoassay (ELISA) using kits for testosterone (Calbiotech, Spring Valley, CA, USA), 17β-estradiol (BQ, San Diego, CA, USA), and P450 aromatase (Cloud-Clone Corp, Houston, TX, USA), following the manufacturer’s protocol. The sensitivity of these ELISA kits was, 0.1ng/ml for testosterone, 10 pg/ml for 17β-estradiol and 0.054 ng/ml for aromatase. The intra-assay and inter-assay coefficient of variability was <10% and <12% respectively.

Patients were divided into ischemic stroke and control groups. Stroke was defined as an acute-onset focal neurological deficit with confirmation by radiographic imaging (CT or MRI). Patients who presented with focal neurological deficits with subsequent resolution of symptoms and no evidence of ischemia on CT/MRI were included in the control group (most were patients with a diagnosis of transient ischemic attack, seizures, complex migraines, or hypertensive encephalopathy). Exclusion criteria were age <56 years, hemorrhagic stroke, any malignancy, autoimmune disease, immunosuppressive, hormone replacement therapy, testosterone replacement or steroid therapy including use of oral contraceptives. Demographic data including past medical history was collected from stroke patient database. Outcome measures were National Institutes of Health Stroke Scale (NIHSS; range, 0 to 42, with higher scores indicating a greater deficit) at discharge and modified Rankin score (mRS, range of 0 [no symptoms] to 6 [death]). Premorbid (baseline mRS) and mRS at the time of hospital discharge were collected by patient chart review. Change in mRS (discharge-premorbid) was used for analysis (14).
SAS and graphpad PRISM software was used for data analysis. Two-way ANOVA was used to compare hormone levels between stroke/control and women/men groups. Post-hoc subgroup comparisons within women and men were provided and adjusted for multiple testing by Sidak method. Spearman correlation coefficient was calculated for hormone levels with NIHSS at the time of discharge and change in mRS (discharge- premorbid mRS)(14). We performed univariate analysis for age, NIHSS, smoking, diabetes, history of cancer on each hormone. Variables with a p value less than 0.1 in the univariate analyses were included in a multivariate linear regression to control for confounders. The criterion of statistical significance in the final model was set at 0.05.

Results

Baseline characteristics of our study population are shown in Table 1 and 2. There was no statistically significant difference in comorbidities including hypertension, hyperlipidemia, diabetes mellitus type 2 and atrial fibrillation in stroke vs. controls. Table 2 shows the stroke cohort demographics and outcomes. Women were older (79.2±10.4 years) at the time of stroke as compared to men (72.8±10 years), as described previously (15). Women had higher median discharge NIHSS (Men 2±3 vs. Women 3±9, p=0.032) and change in mRS, (calculated as discharge- premorbid mRS), men 2±3 vs. women 4±2, p=0.009, indicating worse outcomes, which has been seen in previous studies (16).

Table 1
Patient Demographics for stroke, n = 75 vs. controls, n = 27: There was no significant difference in premorbid conditions including hypertension, hyperlipidemia, Type 2 diabetes mellitus, atrial fibrillation or smoking in stroke versus controls.

| Baseline characteristics     | Stroke | Controls | P value |
|------------------------------|--------|----------|---------|
| Hypertension, n (%)          | 57 (76.0%) | 20 (74.1%) | 0.842   |
| Hyperlipidemia, n (%)        | 46 (61.3%) | 14 (51.9%) | 0.391   |
| Heart disease, n (%)         | 29 (38.7%) | 8 (29.6%)  | 0.402   |
| Type 2 Diabetes Mellitus, n (%) | 23 (30.7%) | 7 (25.9%)  | 0.643   |
| Atrial Fibrillation, n (%)   | 23 (30.7%) | 5 (18.5%)  | 0.316   |
| Smoking, n (%)               | 14 (18.7%) | 2 (7.4%)   | 0.225   |
Table 2
Patient Demographics for men and women with stroke: Women were significantly older at the time of stroke as compared to men, p = 0.016. There was no significant difference in premorbid conditions including hypertension, hyperlipidemia, Type 2 diabetes mellitus, atrial fibrillation or smoking in men vs. women with stroke. Men had significantly higher heart disease history as compared to women, p = 0.036 in our patient population. Women had significantly worse outcomes as compared to men, in terms of discharge NIHSS, p = 0.032 and change in mRS, p = 0.009.

| Stroke category and Outcomes | Men (n = 43) | Women(n = 32) | P value |
|-----------------------------|-------------|---------------|---------|
| Age ( Mean ± SD)            | 72.8 ± 10   | 79.2 ± 10.4   | 0.016   |
| Hypertension, n (%)         | 33 (76.7%)  | 24 (75.0%)    | 0.861   |
| Hyperlipidemia, n (%)       | 29 (67.4%)  | 17 (53.1%)    | 0.208   |
| Heart disease, n (%)        | 21 (48.8%)  | 8 (25.0%)     | 0.036   |
| Type 2 Diabetes Mellitus, n (%) | 12 (27.9%) | 11 (34.4%)    | 0.548   |
| Atrial Fibrillation, n (%)  | 11 (25.6%)  | 12 (37.5%)    | 0.268   |
| Smoking, n (%)              | 11 (25.6%)  | 3 (9.4%)      | 0.132   |
| NIHSS on admission, median (IQR) | 7(12)     | 13(18)        | 0.144   |
| NIHSS at discharge, median (IQR) | 2(3)      | 3(9)          | 0.032   |
| Cardio embolic, n (%)       | 21 (48.8%)  | 22 (68.8%)    | 0.085   |
| Large Artery Atherosclerosis, n (%) | 7 (16.3%) | 4 (12.5%)    | 0.749   |
| Small Vessel Disease, n (%) | 6 (14.0%)   | 3 (9.4%)      | 0.724   |
| Undetermined Etiology, n (%)| 9 (20.9%)   | 3 (9.4%)      | 0.177   |
| Baseline modified Rankin Score, median (IQR) | 0(1)     | 0(3)          | 0.084   |
| Change in modified Rankin Score, median (IQR) | 2(3)     | 4(2)          | 0.009   |
| [discharge mRS- premorbid mRS ] |           |               |         |
| Mortality                   | 5 (11.63%)  | 5 (15.63%)    | 0.736   |

We first compared levels of sex hormones in stroke patients with controls. There was no significant difference in estradiol levels after stroke in men (p=0.86) or women (p=0.10), (Figure 1).

In men, testosterone significantly decreased after stroke as compared with controls (1.83±0.12 vs 2.86±0.65, p=0.01). No difference in testosterone levels was seen in women after stroke (p=0.71), Figure 2. There was a significant main effect of sex (F (1, 98) =26.27, p<0.0001) and a sex by stroke interaction (F (1, 98) =5.24, p=0.02).

Aromatase levels were significantly increased in women after stroke as compared with controls (2.27±0.22 vs 0.97±0.22, p=0.002), but not in men (p=0.84), Figure 3. For aromatase, there was a
significant main effect of stroke (F (1, 98) =9.09, p<0.003) and sex by stroke interaction (F (1, 98) =5.72, p<0.01).

In women, there was a significant positive correlation between estradiol levels and NIHSS at the time of discharge, r=0.45, p=0.01. Similarly, estradiol levels positively correlated with change in mRS score, r=0.38, p=0.02 in women. This correlation was also seen in change in mRS, r=0.3, p=0.04 in men, but not in discharge NIHSS, r=0.26, p=0.1. Testosterone levels had a positive correlation with discharge NIHSS in women, r=0.44, p=0.01. There was no significant correlation of testosterone level with NIHSS in men or with change in mRS score in men or women, p>0.05.

No significant correlation was seen between aromatase and NIHSS (Men, r=-0.3, p=0.06, Women= 0.3, p=0.09,) or change in mRS score (Women r=-0.07, p=0.6, Men, r=-0.2, p=0.1). We used a multivariate regression model and controlled for factors like diabetes mellitus, hypertension, hyperlipidemia, age and NIHSS at time of admission, and serum levels of estradiol were still independently associated with mRS in men and women.

Discussion

Our study shows that aromatase levels are significantly increased in post-menopausal women after acute ischemic stroke when measured within 24 hours from symptom onset. Testosterone levels significantly decrease in men at this time point. No significant difference in estradiol levels was seen at 24 hours post ischemic stroke in either sex, although there was a trend for increased estradiol levels in women with stroke. Interestingly, there was a significant positive correlation between estradiol levels and change in mRS (functional outcome measure), regardless of sex.

In intrauterine life, sexual differentiation of the brain occurs by aromatization of androgens to estrogens (9). It has been shown that neurotoxic insult to the brain (induced by systemic administration of kainic acid), leads to increased aromatase expression in astrocytes (17). In spontaneously hypertensive rats, aromatase was elevated at 24 h and at 8 days after focal cerebral ischemia in the penumbra, specifically in the astrocytic processes (11). The expression of aromatase has also been known to be sex specific. Aromatase activity and expression was found to be greater in female than in male primary cultured cortical astrocytes. Arimidex, an aromatase inhibitor, abolished sex differences in astrocytic cell death induced by oxygen glucose deprivation (OGD), while addition of estradiol protected both sexes. This implied that local estradiol production by aromatase is protective in both sexes (18). Studies in aromatase knock out mice (ArKO) further clarified the role of aromatase. Female ArKO mice subjected to reversible middle cerebral artery occlusion had larger infarcts compared to wild type mice. Similarly, wild type female mice treated chronically with the aromatase inhibitor, fadrozole, had more ischemic damage when compared with ovariectomized females, suggesting that extragonadal estradiol is also important for neuroprotection (12). The role of aromatase in cardiovascular disease has also been highlighted by studies in breast cancer patients who were administered aromatase inhibitors (19). A recent study demonstrated increased risks of heart failure and cardiovascular mortality in patients taking aromatase
inhibitors as compared with patients taking tamoxifen (20). Administration of the specific aromatase inhibitor, fadrozole, in male rats enhanced the neurodegenerative effects of kainic acid and this was reversed by administration of estradiol, confirming that neuroprotective effects of aromatase are mediated by estradiol (21). Consistent with these reports in preclinical literature, our clinical study suggests that the aromatization pathway may become active in the event of brain injury, as evidenced by the increased levels of serum aromatase seen after stroke in women. This may be an early endogenous protective mechanism of the brain activated by transcription factors like hypoxia inducible factor or cytokines(11). Future studies on the dynamics of these transcription factors, cytokines and their associations with sex hormone levels may assist in further deciphering the role of these sex hormones in ischemic stroke.

Although no significant difference in estradiol levels was seen after stroke, we found a significant positive correlation between estradiol levels and change in mRS, regardless of sex, which suggests that increased peripheral estradiol level may be associated with a higher mRS, suggestive of worse outcomes. This has been shown in previous studies in elderly women (22-24). This correlation highlights the complex and long debated role of estradiol in stroke. Boys are known to have higher stroke incidence compared to girls. In fact, it has been seen that for each 1 nmol/liter increase in testosterone in young boys, there was a 1.3 fold increase in risk of stroke (25). This epidemiology reverses with advanced age, and elderly women have higher stroke incidence and worse outcomes, which is often attributed to the loss of estrogen at menopause. Preclinical studies in stroke models have shown a robust neuroprotective effect of estrogen (5), but this was not recapitulated in early clinical trials. Both the WHI and WEST trials of estrogen supplementation led to increased mortality in post-menopausal women (6, 7), although issues with trial design, including the dose, type and timing of estrogen supplementation were raised. The Kronos Early Estrogen Prevention Study (KEEPS) study found that neither oral nor transdermal estrogens affected the progression of atherosclerosis (measured as CIMT, carotid-artery intima–media thickness), when given to recently postmenopausal women (26). On the other hand, Early versus Late Intervention Trial with Estradiol (ELITE) found that oral estradiol therapy (when initiated within 6 years of menopause) was associated with less progression of subclinical atherosclerosis (measured as CIMT) (27). It appears that the type, timing of therapy and the dose response effect of estradiol on the vasculature may be important in determining the benefits of exogenous estrogen for stroke prevention. We speculate that higher post stroke injury (as gauged by worse outcomes, in this case mRS) causes increased aromatase expression and that in turn attempts to increase estradiol levels to protect the brain. However, these results should be interpreted with caution, as causality cannot be determined with a correlation. We did not see any significant difference in estradiol levels with stroke, there was only an incremental trend. This may be due to a few reasons. It is possible that estradiol levels are not elevated in the hyperacute phase after stroke and increase later than the 24 hour time period. This can be ascertained in future studies as we did not perform a longitudinal analysis. Another possible explanation may be that the peripheral endogenous levels of estradiol in the serum are not an accurate representation of the sex steroid milieu in the brain after an injury. Moreover, a low patient sample size to study differences in estradiol levels was one of the limitations of this study.
We also found decreased testosterone levels in men after stroke. This has been reported previously in preclinical models of stroke (28) and also in men (29), which may be due to an acute stress response leading to decreased testosterone levels. However, it is possible that decreasing androgens is a protective mechanism in men. The use of testosterone therapy has been associated with increased risk of adverse cardiovascular outcomes in some studies (30), while others have shown benefit of testosterone replacement therapy, therefore making the role of testosterone in stroke and cardiovascular disease unclear (31). Our study did not find any correlation of testosterone levels with mRS but again, causality is difficult to establish at one time point after stroke.

**Limitations**

This study had some limitations which should be considered. Due to limited number of patients meeting the inclusion and exclusion criteria, our sample size was relatively small, especially for multivariate analysis. Obesity is a known common co-morbidity with cerebrovascular diseases, and adipose tissue is a significant source of aromatase (32). Our database did not record body mass index for most patients and therefore obesity was not accounted for in the multivariate regression model comparing hormone levels. In addition, only total hormone levels were measured by ELISA. It would be interesting to see the distribution between free, total and sex hormone binding globulin bound fractions in future studies. Unlike preclinical studies, it is difficult to obtain pre-stroke serum samples in human stroke biorepositories. Therefore, although the control population does make an adequate comparative group, the pre-stroke differences in hormone levels in this patient population could not be ascertained in this study. It should also be realized that the levels of peripheral endogenous hormones may not simulate the endogenous levels of sex steroids in the injured brain. Finally, this study was performed on serum samples at only 24 hour time point after stroke. Future studies assessing the hormone levels longitudinally would help us in understanding the complex dynamics of sex steroids after stroke.

**Perspectives and Significance:**

In summary, our study demonstrated an increase in aromatase levels after stroke in post-menopausal women. Aromatization may be a protective mechanism by which estradiol is produced locally in the brain (33). We speculate that higher injury post stroke (as determined by higher NIHSS and mRS) accelerates the aromatization process, at least acutely. This is the first study to measure the milieu of sex steroids after stroke in both men and women. This study may add some value in understanding the roles of sex hormones and their contributions to the sexual dimorphism in ischemic stroke.

**Declarations**

**Ethics approval and consent to participate:** This study was approved by IRB at Hartford Hospital, IRB number: HHC-2014-0159

**Consent for publication:** Not applicable
Availability of data and materials: All data generated or analysed during this study are included in this published article.

Competing interests: The authors declare that they have no competing interests

Funding: Supported in part by NINDS R01NS1087795 and R37NS096493 (to LDM)

Authors' contributions: PF performed the hormone ELISA. MROR, SC, were involved in patient sample collection, processing. LZ did statistical analysis. IS extracted demographics from redcap. BM and LDM designed the study, interpreted the data and wrote the manuscript. All authors read and approved the final manuscript

Acknowledgements: Not applicable

References

1. Manwani B, McCullough LD. Sexual dimorphism in ischemic stroke: lessons from the laboratory. Womens Health (Lond). 2011;7(3):319-39.
2. Reeves MJ, Bushnell CD, Howard G, Gargano JW, Duncan PW, Lynch G, et al. Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol. 2008;7(10):915-26.
3. Girijala RL, Sohrabji F, Bush RL. Sex differences in stroke: Review of current knowledge and evidence. Vasc Med. 2017;22(2):135-45.
4. Krause DN, Duckles SP, Pelligrino DA. Influence of sex steroid hormones on cerebrovascular function. J Appl Physiol (1985). 2006;101(4):1252-61.
5. Alkayed NJ, Harukuni I, Kimes AS, London ED, Traystman RJ, Hurn PD. Gender-linked brain injury in experimental stroke. Stroke. 1998;29(1):159-65; discussion 66.
6. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progesterin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-33.
7. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001;345(17):1243-9.
8. Miller VM, Harman SM. An update on hormone therapy in postmenopausal women: mini-review for the basic scientist. Am J Physiol Heart Circ Physiol. 2017;313(5):H1013-H21.
9. Roselli CE, Liu M, Hurn PD. Brain aromatization: classic roles and new perspectives. Semin Reprod Med. 2009;27(3):207-17.
10. Bakker J, Baum MJ. Role for estradiol in female-typical brain and behavioral sexual differentiation. Front Neuroendocrinol. 2008;29(1):1-16.
11. Carswell HV, Dominiczak AF, Garcia-Segura LM, Harada N, Hutchison JB, Macrae IM. Brain aromatase expression after experimental stroke: topography and time course. J Steroid Biochem Mol
12. McCullough LD, Blizzard K, Simpson ER, Oz OK, Hurn PD. Aromatase cytochrome P450 and extragonadal estrogen play a role in ischemic neuroprotection. J Neurosci. 2003;23(25):8701-5.

13. Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, Krueger KE, et al. Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res. 2009;8(1):113-7.

14. Ganesh A, Renoux C. Letter by Ganesh and Renoux Regarding Article, "Sex Differences and Functional Outcome After Intravenous Thrombolysis". Stroke. 2017;48(11):e329.

15. Kelly-Hayes M. Influence of age and health behaviors on stroke risk: lessons from longitudinal studies. J Am Geriatr Soc. 2010;58 Suppl 2:S325-8.

16. Phan HT, Blizzard CL, Reeves MJ, Thrift AG, Cadilhac D, Sturm J, et al. Sex Differences in Long-Term Mortality After Stroke in the INSTRUCT (INternational STRoke oUtComes sTudy): A Meta-Analysis of Individual Participant Data. Circ Cardiovasc Qual Outcomes. 2017;10(2).

17. Garcia-Segura LM, Wozniak A, Azcoitia I, Rodriguez JR, Hutchison RE, Hutchison JB. Aromatase expression by astrocytes after brain injury: implications for local estrogen formation in brain repair. Neuroscience. 1999;89(2):567-78.

18. Liu M, Hurn PD, Roselli CE, Alkayed NJ. Role of P450 aromatase in sex-specific astrocytic cell death. J Cereb Blood Flow Metab. 2007;27(1):135-41.

19. Abdel-Qadir H, Amir E, Fischer HD, Fu L, Austin PC, Harvey PJ, et al. The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer. Eur J Cancer. 2016;68:11-21.

20. Khosrow-Khavar F, Filion KB, Bouganim N, Suissa S, Azoulay L. Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study. Circulation. 2020;141(7):549-59.

21. Azcoitia I, Sierra A, Veiga S, Honda S, Harada N, Garcia-Segura LM. Brain aromatase is neuroprotective. J Neurobiol. 2001;47(4):318-29.

22. Pappa T, Vemmos K, Mantzou E, Savvari P, Stamatakopoulos K, Alevizaki M. Estradiol levels predict short-term adverse health outcomes in postmenopausal acute stroke women. Eur J Neurol. 2012;19(10):1300-4.

23. Lee JS, Yaffe K, Lui LY, Cauley J, Taylor B, Browner W, et al. Prospective study of endogenous circulating estradiol and risk of stroke in older women. Arch Neurol. 2010;67(2):195-201.

24. Maggio M, Ceda GP, Lauretani F, Bandinelli S, Ruggiero C, Guralnik JM, et al. Relationship between higher estradiol levels and 9-year mortality in older women: the Invecchiare in Chianti study. J Am Geriatr Soc. 2009;57(10):1810-5.

25. Normann S, de Veber G, Fobker M, Langer C, Kenet G, Bernard TJ, et al. Role of endogenous testosterone concentration in pediatric stroke. Ann Neurol. 2009;66(6):754-8.
26. Miller VM, Naftolin F, Asthana S, Black DM, Brinton EA, Budoff MJ, et al. The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned? Menopause. 2019;26(9):1071-84.

27. Hodis HN, Mack WJ, Henderson VW, Shoupe D, Budoff MJ, Hwang-Levine J, et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. N Engl J Med. 2016;374(13):1221-31.

28. Manwani B, Bentivegna K, Benashski SE, Venna VR, Xu Y, Arnold AP, et al. Sex differences in ischemic stroke sensitivity are influenced by gonadal hormones, not by sex chromosome complement. J Cereb Blood Flow Metab. 2015;35(2):221-9.

29. Jeppesen LL, Jorgensen HS, Nakayama H, Raaschou HO, Olsen TS, Winther K. Decreased serum testosterone in men with acute ischemic stroke. Arterioscler Thromb Vasc Biol. 1996;16(6):749-54.

30. Vigen R, O’Donnell CI, Baron AE, Grunwald GK, Maddox TM, Bradley SM, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829-36.

31. Loo SY, Chen BY, Yu OHY, Azoulay L, Renoux C. Testosterone replacement therapy and the risk of stroke in men: A systematic review. Maturitas. 2017;106:31-7.

32. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89(6):2548-56.

33. Kelicen-Ugur P, Cincioglu-Palabiyik M, Celik H, Karahan H. Interactions of Aromatase and Seladin-1: A Neurosteroidogenic and Gender Perspective. Transl Neurosci. 2019;10:264-79.

**Figures**

Serum Estradiol levels (pg/ml)

![Graph showing serum estradiol levels in men and women with control and stroke groups compared.](image-url)
Figure 1

Serum Estradiol levels in pg/ml. There was no significant change in estradiol levels 24 hours post stroke in men or women. In women, the estradiol levels trended up after stroke but did not reach significance.

Serum Aromatase levels (ng/ml)

![Graph showing serum aromatase levels](image)

Figure 3

Serum Aromatase levels in ng/ml. The serum aromatase levels significantly increased in women after stroke. No such change was seen in men. **p=0.002